AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21147163 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine infusion (cholinergic challenge)
Number of subjects: 0
Study 21147163 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-gender-education matched veterans)
Number of subjects: 0
Study 20939783 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) involving orthopedic implants
Number of subjects: 0
Study 20939783 — intervention group
Group type: EXPERIMENTAL
Intervention: Study design improvements
Number of subjects: 0
Study 20939783 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges in RCTs
Number of subjects: 0
Study 18175843 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (15 mg/kg)
Number of subjects: 210
Study 15088870 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulfate (CS) combined with demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 19
Study 15088870 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (ePTFE) combined with demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 19
Study 10688340 — intervention group
Group type: EXPERIMENTAL
Intervention: Low TENS treatment
Number of subjects: 28
Study 10688340 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 9058222 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 20
Study 9058222 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 20
Study 9058222 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium and Vecuronium
Number of subjects: 20
Study 1558292 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 ml of 100% alcohol/kg body weight)
Number of subjects: 30
Study 1558292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1558292 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 6234558 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgranules of dihydroergotamine (30 mg/24 hours)
Number of subjects: 30
Study 6234558 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine solution (similar dose)
Number of subjects: 30
Study 30468761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PnR)
Number of subjects: 176
Study 30468761 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 176
Study 29533110 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immunomodulating enteral nutrition (Reconvan, Fresenius Kabi)
Number of subjects: 98
Study 29533110 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (Peptisorb, Nutricia)
Number of subjects: 98
Study 27147077 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (low-level laser 650 nm with 50 mW power applied at each acupoint for 30 s, energy density of 1.8 J/cm²)
Number of subjects: 40
Study 27147077 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (3 months duration for both groups)
Number of subjects: 40
Study 25270701 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical laboratory screenings (serum, urine, complete blood cell counts, standard blood chemistry panels, urinalysis)
Number of subjects: 171
Study 25270701 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal laboratory test results associated with kidney disease
Number of subjects: 171
Study 22260918 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery (OGS)
Number of subjects: 49
Study 22260918 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthodontic treatment only)
Number of subjects: 49
Study 20818855 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of ABVD followed by 30 Gy of radiation therapy (group 1)
Number of subjects: 1370
Study 20818855 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of ABVD followed by 20 Gy of radiation therapy (group 2)
Number of subjects: 1370
Study 20818855 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of ABVD followed by 30 Gy of radiation therapy (group 3)
Number of subjects: 1370
Study 20818855 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of ABVD followed by 20 Gy of radiation therapy (group 4)
Number of subjects: 1370
Study 20818855 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of ABVD and 30 Gy of radiation therapy (group 1)
Number of subjects: 1370
Study 18295445 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (Cardio)
Number of subjects: 50
Study 18295445 — intervention group
Group type: COMPARATOR
Intervention: Flexibility/balance (Flex)
Number of subjects: 50
Study 18295445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio
Number of subjects: 50
Study 18295445 — intervention group
Group type: COMPARATOR
Intervention: Flex
Number of subjects: 50
Study 18295445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio and Flex
Number of subjects: 50
Study 16155169 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection without aspiration (group A)
Number of subjects: 60
Study 16155169 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous ethanol injection with aspiration (group B)
Number of subjects: 60
Study 14621286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution (SP)
Number of subjects: 201
Study 14621286 — intervention group
Group type: COMPARATOR
Intervention: Bisacodyl combined with repeated water enemas (BE)
Number of subjects: 201
Study 10827332 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant(R) contraceptive implants
Number of subjects: 1210
Study 8675159 — intervention group
Group type: EXPERIMENTAL
Intervention: Venovenous bypass (VVBP)
Number of subjects: 77
Study 8675159 — intervention group
Group type: COMPARATOR
Intervention: No venovenous bypass (Control group)
Number of subjects: 77
Study 1888824 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 7.5 mg
Number of subjects: 314
Study 1888824 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 314
Study 1888824 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 314
Study 1888824 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 314
Study 457901 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodramatic Double method
Number of subjects: 64
Study 457901 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflection method
Number of subjects: 64
Study 457901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture method
Number of subjects: 64
Study 457901 — intervention group
Group type: COMPARATOR
Intervention: No-training control
Number of subjects: 64
Study 30525935 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified protocol for transdiagnostic treatment of emotional disorders
Number of subjects: 223
Study 30525935 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-disorder protocol targeting principal diagnosis
Number of subjects: 223
Study 30525935 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 223
Study 30793857 — intervention group
Group type: COMPARATOR
Intervention: Ostomy management reinforcement education (OMRE) - Control group (n = 20)
Number of subjects: 60
Study 30793857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy management reinforcement education (OMRE) - Experimental group 1 (n = 20)
Number of subjects: 60
Study 30793857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy management reinforcement education (OMRE) - Experimental group 2 (n = 20)
Number of subjects: 60
Study 30793857 — intervention group
Group type: COMPARATOR
Intervention: Ostomy management reinforcement education (OMRE) - Control vs Experimental groups
Number of subjects: 60
Study 27890020 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice architecture intervention (improving visibility and quality of fresh produce)
Number of subjects: 575
Study 27890020 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 575
Study 27890020 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice architecture intervention
Number of subjects: 575
Study 27890020 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 575
Study 25963064 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Blocker Therapy
Number of subjects: 877
Study 23748485 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg IV (PAD)
Number of subjects: 40
Study 23748485 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 24 mg orally (OAD)
Number of subjects: 40
Study 21135869 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily for 12 weeks
Number of subjects: 466
Study 21135869 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (RE+ patients)
Number of subjects: 466
Study 21135869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 19590333 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of International Classification of Injury Severity Score (ICISS) for individual patient risk stratification.
Number of subjects: 30
Study 19590333 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression predictive model for mortality using ICISS survival probability (Ps).
Number of subjects: 30
Study 17846455 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 192
Study 17846455 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-mediated intervention
Number of subjects: 192
Study 17846455 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-only intervention
Number of subjects: 192
Study 17256680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual intradermal vaccination (0.1 mL at two sites)
Number of subjects: 0
Study 17256680 — intervention group
Group type: COMPARATOR
Intervention: Conventional subcutaneous vaccination method
Number of subjects: 0
Study 12598499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mixed micellar K(1) 1 mg
Number of subjects: 44
Study 12598499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mixed micellar K(1) 2 mg
Number of subjects: 44
Study 12598499 — intervention group
Group type: COMPARATOR
Intervention: Oral mixed micellar K(1) 2 mg (compared to healthy infants)
Number of subjects: 44
Study 10080041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicodermal patch
Number of subjects: 101
Study 10080041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicodermal patch with psychosocial treatment
Number of subjects: 101
Study 8774986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0
Study 8774986 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0
Study 8774986 — intervention group
Group type: COMPARATOR
Intervention: Rebamipide
Number of subjects: 0
Study 1971117 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem
Number of subjects: 66
Study 1971117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 43554 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 0
Study 43554 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam
Number of subjects: 0
Study 31740426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) followed by oral ramipril for 12 weeks
Number of subjects: 0
Study 31740426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29908297 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous zoledronic acid (ZOL) every 3 months
Number of subjects: 70
Study 29908297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27639211 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 85
Study 27639211 — intervention group
Group type: COMPARATOR
Intervention: Medium-fidelity simulation
Number of subjects: 85
Study 24084497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 177
Study 24084497 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 177
Study 21950312 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg daily for 4 weeks followed by randomization to treatment or placebo for 36 weeks
Number of subjects: 115
Study 21950312 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 115
Study 21950312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 20684019 — intervention group
Group type: EXPERIMENTAL
Intervention: KIDNET (narrative exposure therapy)
Number of subjects: 26
Study 20684019 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 26
Study 18277346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg daily for 5 days after abortion (Group A)
Number of subjects: 466
Study 18277346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg daily for 3 days after abortion (Group B)
Number of subjects: 466
Study 18277346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg daily one day before and 2 days after abortion (Group C)
Number of subjects: 466
Study 15637459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10 mg/day)
Number of subjects: 49
Study 15637459 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (2-8 mg/day)
Number of subjects: 49
Study 15637459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 49
Study 15637459 — intervention group
Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 49
Study 11954884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally three times a day
Number of subjects: 12
Study 11954884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10526739 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 94
Study 10526739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 94
Study 7670452 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink containing 1 g.kg‐1 of carbohydrate four times daily
Number of subjects: 14
Study 7670452 — intervention group
Group type: COMPARATOR
Intervention: Flavored placebo
Number of subjects: 14
Study 2404876 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemical test using monoclonal antibodies to breast-tumor-associated antigens (BTAA)
Number of subjects: 846
Study 2404876 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemical diagnosis
Number of subjects: 846
Study 6770731 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 0.5 mg/kg of body weight, intravenously every 6 h for 72 h
Number of subjects: 44
Study 6770731 — intervention group
Group type: COMPARATOR
Intervention: Placebo, intravenously every 6 h for 72 h
Number of subjects: 44
Study 30606083 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-native listeners (Dutch, Finnish, French)
Number of subjects: 0
Study 30606083 — intervention group
Group type: COMPARATOR
Intervention: Native listeners
Number of subjects: 0
Study 30606083 — intervention group
Group type: EXPERIMENTAL
Intervention: High proficiency in non-native language
Number of subjects: 0
Study 30606083 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cues (English and Dutch)
Number of subjects: 0
Study 30606083 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed cues (Finnish and French)
Number of subjects: 0
Study 30630622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and whole‐body vibration training (20Hz/2mm for first two sessions, 40Hz/4mm for the rest)
Number of subjects: 61
Study 30630622 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training alone
Number of subjects: 61
Study 30630622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and whole‐body vibration training
Number of subjects: 61
Study 27907978 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU in castor oil (100, 200, 400 mg)
Number of subjects: 10
Study 27907978 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU in SEDDS (100, 200, 400 mg)
Number of subjects: 10
Study 27907978 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU powder formulation (100, 200, 400 mg)
Number of subjects: 10
Study 27907978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 27907978 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU (200 mg, 400 mg) with food
Number of subjects: 10
Study 27907978 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU SEDDS (200 mg, 400 mg) fasting
Number of subjects: 10
Study 23595609 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week cookery skills course with written educational materials
Number of subjects: 116
Study 23595609 — intervention group
Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 116
Study 23595609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookery skills intervention
Number of subjects: 116
Study 23595609 — intervention group
Group type: COMPARATOR
Intervention: Written information alone
Number of subjects: 116
Study 24021804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mode tDCS (anodal over right PPC and cathodal over left PPC)
Number of subjects: 10
Study 24021804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-mode tDCS (anodal over right PPC)
Number of subjects: 10
Study 24021804 — intervention group
Group type: COMPARATOR
Intervention: Sham mode tDCS
Number of subjects: 10
Study 21890618 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasculitic neuropathy at baseline
Number of subjects: 506
Study 21890618 — intervention group
Group type: COMPARATOR
Intervention: Microscopic polyangiitis (MPA)
Number of subjects: 506
Study 21890618 — intervention group
Group type: COMPARATOR
Intervention: Granulomatosis with polyangiitis (Wegener's)
Number of subjects: 506
Study 21890618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure sensory neuropathy
Number of subjects: 506
Study 21890618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vasculitic neuropathy
Number of subjects: 506
Study 21890618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic neuropathy
Number of subjects: 506
Study 18457886 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160mg/amlodipine 5mg
Number of subjects: 94
Study 18457886 — intervention group
Group type: COMPARATOR
Intervention: irbesartan 300mg/HCTZ 12.5mg
Number of subjects: 94
Study 18457886 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160mg/amlodipine
Number of subjects: 94
Study 17671918 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care treatment
Number of subjects: 191
Study 17671918 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 191
Study 15193686 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose levels (measured in mg/dl)
Number of subjects: 829
Study 10705179 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol stimulation in acalculous biliary pain group
Number of subjects: 11
Study 10705179 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK stimulation in acalculous biliary pain group
Number of subjects: 11
Study 10705179 — intervention group
Group type: COMPARATOR
Intervention: CCK stimulation in gallstone patients
Number of subjects: 11
Study 10705179 — intervention group
Group type: COMPARATOR
Intervention: CCK stimulation in normal controls
Number of subjects: 11
Study 9321729 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 440
Study 9321729 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin + Gentamicin
Number of subjects: 440
Study 8458189 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg tds for 24 weeks)
Number of subjects: 0
Study 8458189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8458189 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 3825160 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 3825160 — intervention group
Group type: EXPERIMENTAL
Intervention: K-strophanthine
Number of subjects: 0
Study 31048414 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and IVIg
Number of subjects: 121
Study 31048414 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab and IVIg
Number of subjects: 121
Study 31048414 — intervention group
Group type: COMPARATOR
Intervention: IVIg only
Number of subjects: 121
Study 29773539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored text message based diabetes self management support (SMS4BG) for up to nine months in addition to usual care.
Number of subjects: 366
Study 29773539 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 366
Study 27816090 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled studies
Number of subjects: 0
Study 27816090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat statistical methods
Number of subjects: 0
Study 24793816 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (3.6 mg/kg intravenously every 21 days)
Number of subjects: 602
Study 24793816 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice
Number of subjects: 602
Study 24793816 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Number of subjects: 602
Study 22273498 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-nm diode laser treatment
Number of subjects: 21
Study 22273498 — intervention group
Group type: COMPARATOR
Intervention: Untreated contralateral side
Number of subjects: 21
Study 22273498 — intervention group
Group type: COMPARATOR
Intervention: Comparison between treated and untreated sides
Number of subjects: 21
Study 19664010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 61
Study 19664010 — intervention group
Group type: COMPARATOR
Intervention: i.v. midazolam
Number of subjects: 61
Study 18568379 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE group (n = 20)
Number of subjects: 59
Study 18568379 — intervention group
Group type: COMPARATOR
Intervention: Standard educationally-based treatment group (n = 20)
Number of subjects: 59
Study 18568379 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (n = 19)
Number of subjects: 59